Verrica Pharmaceuticals Receives Complete Response Letter from the FDA identifying deficiencies at a facility of a Contract Manufacturer for its New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
September 20, 2021 16:05 ET
|
Verrica Pharmaceuticals Inc.
No Specific Deficiencies Related to the Manufacturing of VP-102 Identified by FDA in its General Inspection of a Facility of the Contract Manufacturer No Clinical, Safety or CMC Issues Specific to...
Verrica Pharmaceuticals Reports Second Quarter 2021 Financial Results
August 10, 2021 07:30 ET
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., Aug. 10, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...
Verrica Pharmaceuticals Announces Appointment of Terry Kohler as Chief Financial Officer
July 09, 2021 07:30 ET
|
Verrica Pharmaceuticals Inc.
Company strengthens management team in anticipation of the potential commercial launch of VP-102, if approved WEST CHESTER, Pa., July 09, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc....
Verrica Pharmaceuticals Announces Extension of FDA Review Period of its NDA for VP-102 for the Treatment of Molluscum Contagiosum
May 28, 2021 07:30 ET
|
Verrica Pharmaceuticals Inc.
– Prescription Drug User Fee Act (PDUFA) goal date extended by three months to September 23, 2021 – WEST CHESTER, Pa., May 28, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”)...
Verrica Pharmaceuticals Announces Participation in the Jefferies Virtual Healthcare Conference
May 26, 2021 07:30 ET
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., May 26, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...
Verrica Pharmaceuticals Announces Participation in the 2021 RBC Capital Markets Global Healthcare Conference
May 12, 2021 07:30 ET
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., May 12, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...
Verrica Pharmaceuticals Reports First Quarter 2021 Financial Results
May 07, 2021 07:30 ET
|
Verrica Pharmaceuticals Inc.
– Expanded commercial team in preparation for potential FDA approval of VP-102 for the treatment of molluscum, which has been assigned a PDUFA goal date of June 23, 2021 – – Raised...
Verrica Pharmaceuticals Announces Participation in the 20th Annual Needham Virtual Healthcare Conference
April 06, 2021 07:30 ET
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., April 06, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...
Verrica Announces Election of Gary Goldenberg, MD, Verrica’s Chief Medical Officer, to Membership in the American Dermatological Association
March 29, 2021 07:30 ET
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., March 29, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (NASDAQ: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...
Verrica Announces Pricing of Public Offering of Common Stock
March 22, 2021 21:31 ET
|
Verrica Pharmaceuticals Inc.
WEST CHESTER, Pa., March 22, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (NASDAQ: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring...